Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801–9.
Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–9.
Cavazza M, Kodra Y, Armeni P, De Santis M, López-Bastida J, Linertová R, et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17 Suppl 1:53–65.
Qu Y, Nie X, Yang Z, Yin H, Pang Y, Dong P, et al. The prevalence of hemophilia in mainland China: a systematic review and meta-analysis. Southeast Asian J Trop Med Public Health. 2014;45(2):455–66.
Yang R, Poon MC, Luke KH, Zhao Y, Sun J, Wang X, et al. Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China. Blood Adv. 2019;3(Suppl 1):34–7.
Dou X, Poon MC, Yang R. Haemophilia care in China: Achievements in the past decade. Haemophilia. 2020;26(5):759–67.
The ministry of labor and social security of the People’s Republic of China. Basic medical insurance, industrial injury insurance drug list (2004 edition). Peking: China labor press; 2004. p. 48.
Ministry of human resources and social security of the People’s Republic of China. The ministry of labor and social security of the People’s Republic of China. In: Basic medical insurance, industrial injury insurance drug list. 2009 edition. Peking(Beijing), China: China labor press; 2009. p. 52.
Ministry of human resources and social security of the People’s Republic of China. The ministry of human resources and social security issued a list of medicines for national basic medical insurance, work injury insurance and maternity insurance. 2017 edition. 2017. http://www.gov.cn/xinwen/2017-02/23/content_5170392.htm. . Accessed 23 Feb 2017.
Sun J, Zhao Y, Yang R, Guan T, Iorio A, Chinese Hero Study G. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study. Haemophilia. 2017;23(1):89–97.
Dong ZH, Chen BB, Li ZQ. Medical insurance and management analysis of hemophilia based on the experience of Shenzhen. China Health Insurance. 2018;1:32–5.
Song XW, Liu W, Xue F, Zhong J, Yang YF, Liu Y, et al. Real-world analysis of haemophilia patients in China: A single centre’s experience. Haemophilia. 2020;26(4):584–90.
Gong GW, Chen YC, Fang PQ, Min R. Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015. Orphanet J Rare Dis. 2020;15(1):137.
Meng Q, Fang H, Liu X, Yuan B, Xu J. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet. 2015;386(10002):1484–92.
Yang Y, Man X, Nicholas S, Li S, Bai Q, Huang L, et al. Utilisation of health services among urban patients who had an ischaemic stroke with different health insurance - a cross-sectional study in China. BMJ Open. 2020;10(10):e040437.
Zhu D, Ding R, Ma Y, Chen Z, Shi X, He P. Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China. BMC Cancer. 2021;21(1):557.
Tencer T, Friedman HS, Li-McLeod J, Johnson K. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. J Manag Care Pharm. 2007;13(9):790–798.
Zhang H, Sun Y, Zhang D, Zhang C, Chen G. Direct medical costs for patients with schizophrenia: a 4-year cohort study from health insurance claims data in Guangzhou city, Southern China. Int J Ment Health Syst. 2018;12:72.
Zhu D, Shi X, Nicholas S, Chen S, Ding R, Huang L, et al. Medical Service Hospital utilization and Direct Medical Cost of Stroke in Urban China. Int J Health Policy Manag. 2020;11(3):277–86.
Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017). Chin J Hematol,2017,38(05):364–370.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):E1-E47.
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd Edition. Haemophilia. 2020;26(S6):1–158.
Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267-e75.
Gharibnaseri Z, Davari M, Cheraghali A, Eshghi P, Ravanbod R, Espandar R, et al. Health care resource hospital utilization and cost of care for haemophilia A and B patients in Iran. Transfus Apher Sci. 2016;54(1):122–6.
Zhou ZY, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457–65.
Rocha P, Carvalho M, Lopes M, Araújo F. Costs and hospital utilization of treatment in patients with hemophilia. BMC Health Serv Res. 2015;15:484.
Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, et al. EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France. Transfusion. 2015;55(7):1787–97.
Globe DR, Curtis RG, Koerper MA, Comm HS. Hospital utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Hospital utilization Group Study (HUGS). Haemophilia. 2004;10:63–70.
Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia. 2000;6(1):23–32.
Escobar MA. Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia. 2010;16 Suppl 3:29–34.
Yan YH, Kung CM. Investigated the hospital utilization and medical resource usage of haemophilia A and B in Taiwan: 2001–2010. Health. 2013;5(10A):1–8.
Ay C, Perschy L, Rejtö J, Kaider A, Pabinger I. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. Ann Hematol. 2020;99(12):2763–71.
Gupta N, Benbouzid A, Belhani M, El Andaloussi M, Maani K, Wali Y, et al. HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries. TH Open. 2019;3(2):e190-e9.
Lee SO, Yu SY. Hospital utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia. J Korean Med Sci. 2016;31(1):33–8.
Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G. Retrospective analysis of differences in annual factor VIII hospital utilization among haemophilia A patients. Haemophilia. 2012;18(2):187–92.
Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders - A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline - Approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4):671–84.
Zhonghua XZ. Chinese guidelines on the treatment of hemophilia (version 2020). Chin J Hematol. 2020;41(4):265–71.
Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semin Thromb Hemost. 1993;19(1):13–24.
Dou XQ, Liu W, Poon MC, Zhang XS, Wu JS, Zeng XJ, et al. Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up. Br J Haematol. 2021;192(5):900–8.
WHO, WFH, ISTH. Delivery of treatment for haemophilia. Haemophilia. 2003;9(4):403–4.
Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P, Ludlam C, et al. Clinical outcomes and resource hospital utilization associated with haemophilia care in Europe. Haemophilia. 2002;8(1):33–43.
Li Z, Wu J, Zhao Y, Liu R, Li K, Zhou Y, et al. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China. Haemophilia. 2018;24(1):126–33.
Yang C, Shen Q, Cai W, et al. Impact of the zero-markup drug policy on hospitalisation expenditure in western rural China: an interrupted time series analysis. Trop Med Int Health. 2017;22(2):180–186.
Shi X, Zhu D, Man X, et al. “The biggest reform to China’s health system”: did the zero-markup drug policy achieve its goal at traditional Chinese medicines county hospitals?. Health Policy Plan. 2019;34(7):483–491.